The external FDA advisory panel assembled by HHS in July 2026 included doctors, pharmacists, and consultants working in the peptide industry

Evolving US policy battles over drug pricing and healthcare affordability, tracking legislation, court rulings, regulatory actions, and industry responses shaping costs, access, and market dynamics.